Who we are

The IFMRS is an international, not for profit federation of musculoskeletal research societies dedicated to promoting excellence in the field of bone and mineral research. The IFMRS mission is to advance musculoskeletal research globally in order to prevent and treat musculoskeletal diseases by collaborating with international societies to share resources, raise public awareness and provide education. 

Leadership - IFMRS Board of Directors

Roland Baron

Roland Baron DDS, PhD
IFMRS Co-Chair

Bente Langdahl

Bente Langdahl MD, DMSc
IFMRS Co-Chair

markus_seibel

Markus Seibel MD, PHD, FRACP
IFMRS Treasurer

 

rick_sumner

D. Rick Sumner PhD
IFMRS Secretary

 

Nicola Napoli (ASBMR)

Nicola Napoli
The American Society for Bone and Mineral Research (ASBMR)

Gudrun Stenbeck (ECTS)

Gudrun Stenbeck
European Calcified Tissue Society (ECTS)

Mark Forwood (ANZBMS)

Mark Forwood
The Australia and New Zealand Bone and Mineral Society (ANZBMS)

Ling Qin (ICMRS)

Ling Qin
International Chinese Musculoskeletal Research Society (ICMRS)

Seiji Fukomoto (JSBMR)

Seiji Fukumoto
Japanese Society for Bone and Mineral Research (JSBMR)

Jennifer Westondorf (ORS)

Jennifer Westondorf
Orthopaedic Research Society (ORS)

Juan Jose Scali (IFMRS representative)
The Iberoamerican Society of Osteology and Mineral Metabolism (SIBOMM)

Robert Blank (ISCD)

Robert Blank
The International Society for Clinical Densitometry (ISCD)

Manuel Naves Diaz (SEIOMM)

Manuel Naves Díaz
Sociedad Española de Investigación Ósea y Metabolismo Mineral (SEIOMM)

Scott Byrne (MEPSA)

Scott Byrne
Molecular & Experimental Pathology Society of Australasia (MEPSA)

Egon Perilli (ANZORS)

Egon Perilli
Australian and New Zealand Orthopaedic Research Society (ANZORS)

Ralph Muller (ISBM)

Ralph Müller
International Society of Bone Morphometry (ISBM)

Claire Edwards (CABS)

Claire Edwards
Cancer and Bone Society (CABS)

Yumie Rhee (KSBMR)

Yumie Rhee
Korean Society for Bone and Mineral Research (KSBMR)

Luca Brun (AAOMM)

Lucas Brun
Asociación Argentina de Osteología y Metabolismo Mineral (AAOMM)

Bram van der Eerden
The International Bone Marrow Adiposity Society (BAMS)

Masaru Ishii
Japanese Society for Osteoimmunology (JSO)

IFMRS Committees and Working Groups

Future Global Leaders

Terms of Reference

Julie Anne Sterling (ASBMR) Co-Chair
Karl Lewis (ORS) Co-Chair
Lin Han (ICMRS)
Toshihide Mizoguchi (JSBMR)

Tania Winzenberg (ANZBMS)
Meghan Lawrence (ASBMR)
Nicolas Bonnet (ECTS)

Education Working Group

Terms of Reference

Mark Forwood (ANZBMS) Chair
Karl Lewis (ORS)
Gudrun Stenbeck (ECTS)

Robert Blank (ISCD)
Nicolas Bonnet (ECTS)

Big Data Working Group

ASBMR (American Society for Bone and Mineral Research)
Lynda Bonewald (Co-chair)
Jane Lian
Doug Kiel
David Karasik
ANZBMS (Australia and New Zealand Bone and Mineral Society)
Emma Duncan (Co-chair)
John Kemp
European Calcified Tissue Society (ECTS)
Fernando Rivadeneira
International Chinese Musculoskeletal Research Society (ICMRS)
Qing Wu

Japanese Society of Bone and Mineral Research (JSBMR)
Yuuki Imai
Yoshiya Tanaka
Ibero American Society of Osteology and Mineral Metabolism (SIBOMM)
Merce Giner
Natalia García Giralt
Orthopaedic Research Society (ORS)
Nidhi Bhutani
Muhammad Farooq Rai
Jennifer Westendorf
Elizabeth Yanik
International Society for Bone Morphometry
Ralph Müller

MUSCULOSKELETAL KNOWLEDGE PORTAL 

Big Data Sub-Group

CHAIR – Douglas Kiel (Big Data Group member/ASBMR)
Lynda Bonewald (Big Data Group co-chair/ASBMR)
Emma Duncan (Big Data Group co-chair/ANZBMS)
Fernando Rivadeneira (ECTS)
Yuuki Imai (JSBMR)
Jennifer Westendorf (ORS)
David Karasik (ASBMR)
Ralph Muller (ISBM)
John Kemp (University of Queensland)

Staff

Federico Moscogiuri (IFMRS)

Federico Moscogiuri
IFMRS CEO

Email: ceo (at) ifmrs.org 

Corporate Partnership and Support

The benefits of Corporate Partnership

By supporting and working with the IFMRS, you will be collaborating with a truly international federation of world-renowned, leading societies, with a combined membership of over 18,000. The best way to do this is via Corporate Partnership.

Corporate partnerships allows the IFMRS to initiate and deliver the activities and projects in our Strategic Plan. There are three tiers of support, with a corresponding level of benefit. All corporate partners will be acknowledged according to their level of support on the IFMRS website.

LEVEL

BENEFITS

COST (1 year)

GOLD
  • Logo and acknowledgement on IFMRS website, including brief description and link to partner website
  • Free ad with company logo and link in all IFMRS newsletters
  • Quarterly virtual meetings with the CEO, including face-to-face at international conferences where possible.

$30,000

SILVER
  • Logo and acknowledgement on IFMRS website, including brief description
  • Company logo and link in all IFMRS newsletters
  • Quarterly virtual meetings with the CEO, including face-to-face at international conferences where possible.

$20,000

BRONZE
  • Logo and acknowledgement on IFMRS website, including brief description
  • Quarterly virtual meetings with the CEO, including face-to-face at international conferences where possible.

$5,000

Please contact the ceo, Federico Moscogiuri, to discuss Corporate Partnership and other support opportunities.

Click on the link to download a copy of our Corporate Partnership Policy.

Corporate Partners

We are grateful to our Corporate Partners:

Kyowa Kirin

Kyowa Kirin is an R&D-based life sciences company with special strengths in biotechnology. The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. www.kyowakirin.com

Ipsen

Ipsen is a global biopharmaceutical company dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases. In Rare Diseases, Ipsen is committed to making high-quality, innovative therapeutic treatments available to people with rare diseases and supporting them and their families with medicines, services and solutions across the entire continuum of care, from diagnosis to treatment follow-up. Its goal is to leave no patient behind. Ipsen has a global presence and capabilities to serve patients around the world: with medicines available in 120 countries and a direct commercial presence in more than 30 countries. For more information on Ipsen, visit www.ipsen.com